Amadix
Madrid · Founded 2010
About Amadix
Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide. The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients). Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
Company Facts
- Founded: 2010
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.1M
- Last round: Debt Financing (Feb 2025)
- Website: http://www.amadix.com
- Phone: +34 983 10 20 60
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/amadix-6861 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.